Bioniche Life Sciences Inc. is a leading clinical stage biotechnology company focused on the development, manufacturing, and commercialization of proprietary and innovative therapeutics for the global human health market. The Company’s anchor product is in Phase III clinical development to treat non-muscle-invasive bladder cancer.
The Company is publicly traded on the Toronto Stock Exchange (TSX: BNC).
The information contained in the Company’s news releases was accurate at the time of posting on this website, but the information may be superseded by subsequent corporate disclosures.
For recent media coverage of Bioniche Life Sciences Inc. click here >>
July 29, 2014
Bioniche Announces Submission of Orphan Drug Designation Application for MCNA in the United States
July 18, 2014
Bioniche Announces Intention to File for Marketing Approval of MCNA in the United States
June 13, 2014
Bioniche Life Sciences Inc. to Present at Bloom Burton & Co. Healthcare Investor Conference